hGH fragment raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-05-24 and is reviewed periodically as new material appears.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
It was agreed to by a previous Progressive Conservative government after DynaLIFE appealed AHS's contractual arrangement for provision of lab services with Sonic Healthcare, an Australian company. Sonic would have provided these services in Edmonton and northern Alberta starting in October 2014, but the contract was cancelled through DynaLIFE's successful appeal. The provincial government announced on December 5, 2022, that the public Alberta Precision Laboratories (APL) was going to be replaced by the private, for-profit DynaLIFE in providing community lab services in Alberta's large municipalities. By early January 2023, wait times had increased for blood tests that used to be routine and rapid. A University of Calgary assistant professor in health law questioned DynaLIFE's cut backs on "staffing or hours".
== Method == SISCAPA is an extension of the well-known gold-standard methods of stable-isotope dilution for quantitation of small molecules by mass spectrometry (MS). Rather than measure an intact protein directly by mass spectrometry, SISCAPA makes use of proteolytic digestion (e.g., with the enzyme trypsin) to cleave sample proteins into smaller peptides ideally suited to quantitation by mass spectrometry. By selecting a target peptide whose sequence occurs only in the selected target protein (a so-called “proteotypic” peptide), the target peptide can serve as a direct quantitative surrogate for the target protein (assuming the digestion process is complete, or at least reproducible). A synthetic version of the target peptide containing a stable isotope label is added in a known amount to the digested sample to serve as an internal standard (SIS). Since the target peptide and SIS are chemically indistinguishable throughout the workflow, but can be measured separately by a mass spectrometer due to the mass difference of the stable isotope label, their ratio provides the desired quantitative estimate of the target peptide amount. The SISCAPA workflow adds a specific enrichment step to the isotope dilution method in which a selected target peptide, together with its associated SIS internal standard, is captured by a sequence-specific anti-peptide antibody.
MRI uses strong magnetic fields to align atomic nuclei (usually hydrogen protons) within body tissues, then uses a radio signal to disturb the axis of rotation of these nuclei and observes the radio frequency signal generated as the nuclei return to their baseline states. The radio signals are collected by small antennae, called coils, placed near the area of interest. An advantage of MRI is its ability to produce images in axial, coronal, sagittal, and multiple oblique planes with equal ease. MRI scans give the best soft tissue contrast of all the imaging modalities. With advances in scanning speed and spatial resolution, and improvements in computer 3D algorithms and hardware, MRI has become an important tool in musculoskeletal radiology and neuroradiology. One disadvantage is that the patient has to hold still for long periods of time in a noisy, cramped space while the imaging is performed. Claustrophobia (fear of closed spaces) severe enough to terminate the MRI exam is reported in up to 5% of patients. Recent improvements in magnet design, including stronger magnetic fields (3 teslas), shortening exam times, wider, shorter magnet bores, and more open magnet designs, have brought some relief for claustrophobic patients. However, for magnets with equivalent field strengths, there is often a trade-off between image quality and open design. MRI has great benefits in imaging the brain, spine, and musculoskeletal system.
== Biosynthesis == Patellamide A originates from a ribosomal peptide, making it a member of the RiPP superfamily of natural products. This was determined after genome sequencing of P. didemi showed a lack of non ribosomal peptide synthetases. The biosynthetic gene cluster for patellamide A contains the genes patA, patB, patC, patD, patE, patF and patG. These genes, when introduced into E. coli, cause the production of patellamide A, definitively confirming their responsibility for patellamide A biosynthesis. The gene patE encodes the precursor peptide that contains the primary sequences of patellamides A and C. It has been proposed by Schmidt et al. that this prepatellamide is heterocyclized to form the oxazoline and thiazoline rings by PatD2. It is proposed that PatG1 is subsequently involved in oxidizing the thiazoline rings to the thiazole rings found in patellamide A. The peptide is then cleaved, possibly by PatA or PatG2, and cyclized, the cyclization is likely aided by adenylation by PatD1, forming the two cyclic peptides, patellamides A and C. Although all the amino acids used in the production of patellamide A are L-amino acids, some of the amino acids found in natural patellamide A are the D-epimers. It is proposed that epimerization of these amino acids occurs spontaneously. This was determined by comparison to a similar system, lissoclinamide 7.
Sources: en.wikipedia.org
The European Aviation Safety Agency (EASA) is tasked by Article 15(4) of Regulation (EC) No 216/2008 of the European Parliament and of the Council of February 20, 2008, to provide an annual review of aviation safety. The Annual Safety Review presents statistics on European and worldwide civil aviation safety. Statistics are grouped according to type of operation, for instance, commercial air transport, and aircraft category, such as aeroplanes, helicopters, gliders, etc. The Agency has access to accident and statistical information collected by the International Civil Aviation Organization (ICAO). States are required, according to ICAO Annex 13, on Aircraft Accident and Incident Investigation, to report to ICAO information, on accidents and serious incidents to aircraft with a maximum certificated take-off mass (MTOM) over 2250 kg. Therefore, most statistics in this review concern aircraft above this mass. In addition to the ICAO data, a request was made to the EASA Member States to obtain light aircraft accident data. Furthermore, data on the operation of aircraft for commercial air transport were obtained from both ICAO and the NLR Air Transport Safety Institute.
Technetium also has numerous nuclear isomers, which are isotopes with one or more excited nucleons. Technetium-97m (97mTc; "m" stands for metastable) is the most stable, with a half-life of 91.1 days and excitation energy 0.097 MeV, followed by technetium-95m (62.0 days, 0.039 MeV), and technetium-99m (6.01 hours, 0.143 MeV). Technetium-99 (99Tc) is a major product of the fission of uranium-235 (235U), making it the most common and most readily available isotope of technetium, and the only one detected in nature. One gram of technetium-99 produces 6.2 × 108 disintegrations per second (in other words, the specific activity of 99Tc is 0.62 GBq/g).
=== Epilepsy === From the results seen in humans with drugs such as Epidiolex and Sativex in scientific studies and reviews, it could be expected that CBD-based products would be helpful to manage seizures in dogs. However, despite the numerous case reports presented by veterinary neurologists supporting the benefits of CBD as adjunctive therapy, as of December 2020, published controlled studies have not shown a statistically significant decrease in the number of seizures across the groups receiving CBD.
Sources: en.wikipedia.org
In March 2025, the company sold its entire stake in Haleon for $3.24 billion to institutional investors. In October 2025, Pfizer entered an agreement with the Trump administration to voluntarily lower US drug prices, which included a three-year exemption from pharmaceutical-specific tariffs, as long as the firm further invests in domestic manufacturing. Pfizer pledged to put $70 billion into US manufacturing and research. In November 2025, Pfizer acquired Metsera to expand its weight-loss drug portfolio in a deal that had the potential to exceed $10 billion.
=== Bacterial or viral === As bacterial and viral infections can both cause the same kinds of symptoms, it can be difficult to distinguish which is the cause of a specific infection. Distinguishing the two is important, since viral infections cannot be cured by antibiotics whereas bacterial infections can.
==== Barack Obama ==== Hitchens supported Barack Obama in the 2008 presidential election. Hitchens criticized Obama's democratic opponent Hillary Clinton writing in a column for the slate "Indifferent to truth, willing to use police-state tactics and vulgar libels against inconvenient witnesses, hopeless on health care and flippant and fast and loose with national security: the case against Hillary Clinton for president is open-and-shut". In an article for Slate he stated, "I used to call myself a single-issue voter on the essential question of defending civilization against its terrorist enemies and their totalitarian protectors, and on that 'issue' I hope I can continue to expose and oppose any ambiguity." He was critical of both main party candidates, Obama and John McCain, but wrote that Obama would be the better choice. Hitchens went on to call McCain "senile", and his choice of running mate Sarah Palin "absurd", calling Palin a "pathological liar" and a "national disgrace". Hitchens also wrote that "Obama is greatly overrated" and that the Obama-Biden ticket "show[s] some signs of being able and willing to profit from experience".
=== Relationship Testing === BRT's Relationship Testing division offers services in Paternity Testing and Family reunification Immigration Testing. DNA testing can identify relationships between parent and child, full or half siblings, grandparent and grandchild, uncles or aunts and nieces or nephews, as well as identical and non-identical twins. The Laboratory is accredited by the AABB (formerly, American Association of Blood Banks). Testing can be performed for submission in legal proceedings (court admissible) or for personal knowledge. Application for immigration to the United States and Canada often requires documentation of biological relationship between a petitioner and his or her beneficiary. DNA testing can be used to prove a relationship if documents are absent or challenged. The US Immigration and Naturalization Service (INS) and United States Citizenship and Immigration Services (USCIS) offices accept DNA testing results from AABB accredited laboratories only.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.